Keytruda Clears Low Hurdle In Stage III Melanoma
Executive Summary
Merck & Co's Keytruda hits endpoint in KEYNOTE-054 as a monotherapy for high-risk patients but the low bar set by the placebo comparator means that rival Opdivo should keep its edge.
You may also be interested in...
Merck's Keytruda Loss In Liver Cancer Could Be Gain For Rivals
The drug demonstrates improvements in overall survival and progression-free survival, but not enough for success in KEYNOTE-240.
Novartis' Growth Driver Tafinlar/Mekinist Picks Up New Melanoma, Thyroid Indications
New FDA labeling brings Tafinlar/Mekinist into adjuvant melanoma setting, but Bristol's competing Opdivo already has captured nearly 50% of the market and is approved regardless of genetic mutation.
Pipeline Watch: Phase III Starts For BL-8040, Trigriluzole, MIN-101
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.